Sedimentation Studies on Human Amylin Fail to Detect Low-Molecular-Weight Oligomers  by Vaiana, Sara M. et al.
Sedimentation Studies on Human Amylin Fail to Detect
Low-Molecular-Weight Oligomers
Sara M. Vaiana,* Rodolfo Ghirlando,y Wai-Ming Yau,* William A. Eaton,* and James Hofrichter*
*Laboratory of Chemical Physics and yLaboratory of Molecular Biology, National Institute of Digestive and Diabetes and Kidney
Diseases, National Institutes of Health, Bethesda, Maryland
ABSTRACT Sedimentation velocity experiments show that only monomers coexist with amyloid ﬁbrils of human islet amyloid-
polypeptide. No oligomers containing ,100 monomers could be detected, suggesting that the putative toxic oligomers are much
larger than those found for the Alzheimer’s peptide, Ab(1-42).
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Human Islet amyloid polypeptide (hIAPP or amylin) is
a 37-residue peptide that is cosecreted with insulin in the
b-cells of the pancreas. It is the main component found in
amyloid deposits of type II diabetes and forms amyloid
ﬁbrils in vitro (1,2). As is the case with other amyloid
peptides, the link between ﬁbril formation and disease is not
yet understood (3–8). Early sedimentation equilibrium
studies of the amyloid b-peptide, Ab(1-40), showed that
ﬁbril formation in this system exhibits a critical concentra-
tion, or solubility, below which no assembly occurs, and that
the principal species in equilibrium with ﬁbril is the Ab
monomer (9,10). No such studies have been carried out for
hIAPP, presumably because its high polymerization propen-
sity makes detection of monomers at this concentration
impossible using conventional probes. In addition, atomic
force and electron microscope studies of ﬁbril formation on
many amyloid peptides have shown the presence of smaller
aggregates, frequently coexisting with mature ﬁbrils and
sometimes appearing only as transient species at early stages
of aggregation (11–15). The role of these species in ﬁbril
assembly and in the disease pathogenesis is still a matter of
debate (8,16–19).
In this communication, we report sedimentation studies
on metastable solutions of hIAPP for which polymeriza-
tion is sufﬁciently slow that ﬁbril formation does not occur
in solution during the time required to carry out the sedi-
mentation velocity experiments. The solutions were either
cleared of any aggregated hIAPP by sedimentation in the
analytical centrifuge or by prior preparative centrifugation at
60 krpm (g ¼ 485,000). The peptide was dissolved directly
in aqueous buffer, without the use of organic solvents or
denaturants. At room temperature and neutral pH, the pep-
tide aggregates rapidly, reducing the monomer concentration
to below the limits of detection. Solutions were therefore
prepared at 4.0C, initially at low pH where solubility
appears to be higher and the rate of ﬁbril formation is much
slower.
Fig. 1 B shows sedimentation velocity proﬁles obtained
for the soluble component of the sample using interference
optics (identical results were obtained with absorbance; see
Supplementary Material) on a precleared sample of hIAPP.
Also shown are the best-ﬁt curves resulting from an analysis
of the distribution of sedimentation coefﬁcients, c(s). The ﬁts
obtained in this analysis are excellent as judged by the
pooled residuals (Fig. 1 A) and their root mean-square devi-
ation. The c(s) distribution shown on the right (blue curve,
Fig. 1 C) shows clearly that the sedimentation proﬁle results
from a single species with an estimated molecular mass of
4.0 6 0.1 kDa (s20,w of 0.65 S). The molecular mass of the
amidated and oxidized form of hIAPP is 3.904 kDa (con-
ﬁrmed by electrospray ionization mass spectrometry per-
formed on the same samples). These experiments therefore
demonstrate that the soluble species is monomeric hIAPP.
After the sedimentation velocity runs, the hIAPP was
resuspended and the absorbance of the solution was mea-
sured while spinning at low speed (3 krpm). The absorbance
decreased relative to that measured on the initially loaded
solution indicating that additional high-molecular-weight
species had formed during the velocity run and accumulated
at the cell bottom. Transmission electron microscopy (TEM)
imaging was performed on samples recovered at the end of
each ultracentrifugation run. A typical result is shown in
Fig. 2. It shows the presence of ﬁbrils as well as other small
aggregates, which include species that have curvy, short,
spherical, or sometimes annular shapes. Similar species have
been previously described in the literature (12,16,20–22).
Equilibrium sedimentation experiments were attempted
on the same (or analogous) samples at 4.0C and 50 krpm,
using both absorbance and interference optics. In all cases,
the concentration proﬁles did not indicate the presence of any
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species larger than monomer; the samples, however, never
truly reached equilibrium (even after 86 h) due to slow and
steady loss of monomer. This indicates that the soluble mono-
mers of Fig. 1 are only metastable relative to larger aggregates
on the timescales of the duration of velocity experiments
(24 h), and eventually precipitate out of solution.
Identical results to those in Fig. 1, A and B, were found for
the soluble supernatant when sedimentation velocity exper-
iments were repeated for different loading concentrations
(Fig. 1 C), without preclearing the samples (Fig. 1 D), at
higher temperature (Fig. 1 E) and different pH (Fig. 1 F). In
all cases, the soluble material consisted of a single species
corresponding to an hIAPP monomer. When samples were
not precleared, signiﬁcant material losses were observedwithin
the ﬁrst few minutes at 60 krpm. Correspondingly, TEM
images showed the presence of more ﬁbrils. When exper-
iments were attempted at pH ¼ 7.4 and higher temperatures
(20C or 30C) all of the hIAPP precipitated during or before
the sedimentation runs, indicating that aggregation kinetics
is too fast (and the solubility too low) for metastable mono-
mers to be observed on timescales required for these experi-
ments.
Importantly, the sedimentation velocity experiments did
not detect appreciable amounts of species with S-values
,15, corresponding to oligomers containing ,100 mono-
mers. We note that in most cases equally good ﬁts were
obtained when data were analyzed in terms of a single
species; that is, the root mean-square deviations for the single
species ﬁts and the ﬁts to a c(s) distribution were indistin-
guishable. The absence of small aggregates shows that there
is a signiﬁcant nucleation barrier to ﬁbril formation. For
example, the maximum concentration of small oligomers
(dimers, trimers) can be estimated to be,;2% of the monomer
concentration, so even these small aggregates must be unstable
by .2.5 kcal/mol relative to monomers.
There is a signiﬁcant literature to document the presence
of oligomers in other amyloid-forming systems. Oligomers
varying in size between dimers and 40–50-mers were observed
FIGURE 1 Summary of sedimentation velocity runs for the soluble component of hIAPP (data collected at 60 krpm). (Left) Typical
sedimentation velocity proﬁles (obtained on a precleared sample at pH 5 4.9, T 5 4C, and c 5 55 mM) shown in terms of interference
fringes versus radius (B), and pooled residuals from the ﬁt (A). For clarity, scans are shown at 50-min intervals (every 10th scan with
every eighth interference data point shown). Lines are best-ﬁt curves obtained from a continuous c(s) analysis. (Right) The c(s)
distributions obtained for: (C) precleared samples at pH5 4.9, T5 4C, c5 68mM (blue), and c5 55mM (red), using interference optics;
(D) samples ﬁltered but not prespun in the preparative centrifuge before loading, at pH5 4.9, T5 4.0C, c5 59 mM, l5 236 nm (cyan),
c5 150 mM, l5 236 nm (blue), c5 230 mM, and l5 280 nm data multiplied by 1.5 for clarity (red); (E) pH5 4.9, T5 20C, and c5 55 mM
using interference optics; and (F) pH dependence at 4.0C, pH 6.2 (red, c5 82 mM, l5 280 nm), pH 7.4 (green, c5 76 mM, l5 280 nm),
and pH 7.9 (blue, c 5 59 mM, l 5 236 nm).
FIGURE 2 Transmission electron micrograph of the resus-
pended cell contents after completion of the sedimentation
velocity runs shows the presence of both ﬁbrillar (left panel) and
nonﬁbrillar (right panels) aggregates.
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by sedimentation velocity in a recent study of b2 microglob-
ulin, the peptide involved in dialysis related amyloidosis (23).
In the case of Ab(142), dimers, trimers, and higher oligo-
mers have been observed and isolated by size exclusion chro-
matography, in samples prepared by dilution from organic
solvents (24–26). These oligomers react with antibodies that
do not react with ﬁbrils, indicating signiﬁcant structural
differences. The more striking result is that the same anti-
bodies react with putative oligomers in solutions of hIAPP,
but not with ﬁbrils. From these results, as well as those on
several other amyloid-forming peptides, Glabe and co-
workers have suggested that soluble amyloid oligomers have
a common structure and share a common toxicity mechanism
(19,26,27).
In their study, Glabe and co-workers did not determine the
size of the soluble oligomers for hIAPP, as they did with
Ab(1-42), where they found that antibody binding required a
minimum of eight monomers. Although our experiments are
not carried out under the identical conditions used in the
antibody assay, our results suggest that the minimum number
of monomers in these putative toxic oligomers is .100.
SUPPLEMENTARY MATERIAL
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